Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;98(7):333-337.
doi: 10.1111/avj.12936. Epub 2020 Mar 2.

Inconsistent efficacy of water-soluble amphotericin B for the treatment of Macrorhabdus ornithogaster in a budgerigar (Melopsittacus undulatus) aviary

H R Baron  1   2 , B C Stevenson  3 , D N Phalen  1   4
Affiliations

Inconsistent efficacy of water-soluble amphotericin B for the treatment of Macrorhabdus ornithogaster in a budgerigar (Melopsittacus undulatus) aviary

H R Baron et al. Aust Vet J. 2020 Jul.

Abstract

Objective: To assess the efficacy of a commercially available in-water amphotericin B treatment for Macrorhabdus ornithogaster.

Design: Clinical treatment trial.

Methods: Faecal shedding of 16 naturally infected budgerigars (Melopsittacus undulatus) was monitored while they were being treated using in-water amphotericin B, as per the manufacturer's instructions, for 10 days. Any birds that remained positive after 10 days received a further 10 day course of treatment. All birds were rechecked 16 days after the end of the second treatment period.

Results: At the conclusion of treatment, 11 birds had stopped shedding M. ornithogaster, and 5 birds were still shedding. Sixteen days after the conclusion of the second treatment period, four birds that were negative after 10 days of treatment were shedding again, and two of the birds that were treated for 20 days were shedding. In addition, one bird from each treatment group died after treatment and before follow-up testing.

Conclusion: These findings represent a 36% treatment failure, suggesting that treatment with the commercially available, water-soluble amphotericin B has inconsistent efficacy against M. ornithogaster in some budgerigars in Australia and is not effective for eliminating it from budgerigar aviaries.

Keywords: Macrorhabdus ornithogaster; amphotericin B; efficacy; macrorhabdus; treatment.

PubMed Disclaimer

References

    1. Tomaszewski EK, Logan KS, Snowden KF et al. Phylogenetic analysis identifies the ‘megabacterium’ of birds as a novel anamorphic ascomycetous yeast, Macrorhabdus ornithogaster gen. nov., sp. nov. Int J Syst Evol Microbiol 2003;53:1201-1205.
    1. Baker JR Megabacteria in diseased and healthy budgerigars. Vet Rec 1997;140:627-627.
    1. Lanzarot P, Blanco JL, Alvarez-Perez S et al. Prolonged fecal shedding of ‘megabacteria’ (Macrorhabdus ornithogaster) by clinically healthy canaries (Serinus canaria). Med Mycol 2013;51:888-891.
    1. Filippich LJ, Perry RA Drug trials against megabacteria in budgerigars (Mellopsittacus undulatus). Aust Vet Pract 1993;23:184-189.
    1. Unknown. iCo Therapeutics announces positive secondary endpoint and advancement into later stage clinical trials - Phase 1 oral amphotericin B, 2018. Press Release, 24 August 2018.

LinkOut - more resources